Opinion|Videos|March 4, 2025
Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC
Experts discuss how they balance safety, efficacy, and overall patient prognosis when selecting third-line treatments for metastatic colorectal cancer (mCRC) and explore how the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, informing treatment decisions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- When selecting third-line treatments for mCRC, how do you balance safety, efficacy, and overall patient prognosis?
- How do the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, and how can these differences inform treatment decisions?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the FDA's Peptide Reversal
2
US Employer Health Care Costs Projected to Rise 9.5% in 2027
3
Student Mental Health, Success Tied to Future Health and Affordability
4
FDA Approves First Orexin Agonist for Narcolepsy Type 1
5